Palmitoyl Tripeptide-5
Skin / Anti-AgingAlso known as: Syn-Coll, Pal-KVK
Mechanism
One of the most potent collagen-stimulating cosmetic peptides available. It mimics a natural protein (thrombospondin-1) that tells skin cells to make more collagen. Studies by Sederma showed up to 119% increase in collagen production. Used in high-end anti-aging serums as a topical alternative to collagen injections.
Technical detail
Palmitoyl-conjugated tripeptide (Lys-Val-Lys) that functions as a thrombospondin-1 (TSP-1) mimetic. TSP-1 activates latent TGF-beta by binding and conformationally changing the latency-associated peptide (LAP). Activated TGF-beta engages TGF-beta R1/R2 receptors on dermal fibroblasts, signaling through Smad2/3 pathway to upregulate COL1A1, COL3A1, and elastin gene transcription. Sederma in-vitro data: 119% increase in collagen I synthesis at 2.5 ppm. Clinical trial (20 volunteers, 84 days): significant reduction in wrinkle volume and depth vs. placebo.
Effects
## Integumentary System — TGF-beta Mediated Collagen Production [Tier 2 — Moderate Human Data] Palmitoyl-Tripeptide-5 (Pal-KVK, trade name Syn-Coll) is a lipopeptide that mimics the mechanism by which Thrombospondin-1 (TSP-1) activates latent TGF-beta. TGF-beta is the master regulator of collagen synthesis in fibroblasts. By activating the TGF-beta pathway via TSP-1 mimicry, Syn-Coll triggers robust collagen I and III synthesis without the fibrogenic/scarring effects seen with supraphysiological TGF-beta (the peptide produces a physiological-level activation). In vitro studies show a dose-dependent increase in procollagen I synthesis (up to 119% increase at optimal concentration). Clinical studies demonstrate wrinkle reduction comparable to retinol at 12 weeks. ## Extracellular Matrix — Collagen Quality [Tier 3 — In Vitro Data] Beyond quantity, Syn-Coll-stimulated collagen fibrils show improved cross-linking and structural organization in vitro. This is attributed to TGF-beta's role in coordinating the entire collagen maturation cascade (procollagen processing, fibril assembly, lysyl oxidase-mediated cross-linking).
Practitioner Guide
## Practical Formulation Guide ### How Syn-Coll Differs From Matrixyl Both Syn-Coll and Matrixyl stimulate collagen, but through different pathways: - **Matrixyl (Pal-KTTKS):** Matrikine signaling — a collagen fragment that tells fibroblasts "collagen was broken down, make more." - **Syn-Coll (Pal-KVK):** TGF-beta activation — mimics the growth factor that directly turns on the collagen gene transcription machinery. - **Practical implication:** These two peptides are synergistic — different inputs converging on the same output (more collagen). Combining them in one formulation is a well-supported strategy. ### Effective Concentrations - **Manufacturer-recommended:** 1-4% of commercial Syn-Coll solution. - **Active peptide:** 50-100 ppm in finished product. ### Formulation Considerations - **pH:** Stable at pH 5.0-7.0. - **Compatibility:** Compatible with all major cosmetic peptides. Specifically validated with Matrixyl, Argireline, and Syn-Ake. - **Vehicle:** Amphiphilic — works in serums and emulsions. ### Where It Fits Syn-Coll is a "collagen amplifier." Pair it with: - **Matrixyl:** Different collagen pathway — additive/synergistic - **Argireline:** Complementary (collagen vs. expression relaxation) - **Matrixyl Synthe'6:** Complementary (Syn-Coll focuses on collagen, Synthe'6 covers 6 ECM components) ### Realistic Expectations - **4 weeks:** Subtle skin texture improvement. Hydration benefit. - **8 weeks:** Measurable wrinkle depth reduction. Improved skin firmness on cutometry. - **12 weeks:** Clinical studies show efficacy comparable to retinol for wrinkle endpoints. Approximately 15-25% wrinkle depth reduction.
Research Summary
## Tier 1 — Strong Clinical Evidence - Mechanism (TSP-1-mediated TGF-beta activation) is biologically well-characterized ## Tier 2 — Moderate Evidence - Clinical studies (DSM, manufacturer) showing wrinkle depth reduction comparable to retinol at 12 weeks - In vitro data: 119% increase in procollagen I synthesis at optimal concentration - Head-to-head comparison with retinol suggesting equivalent wrinkle reduction without irritation ## Tier 3 — Preclinical/Theoretical - Improved collagen fibril quality (cross-linking and organization) in vitro — clinical significance unknown - Potential synergy with Matrixyl (different pathway) — not tested in formal combination clinical study - TGF-beta pathway activation raises theoretical concern about fibrosis — not observed clinically at cosmetic concentrations, but the pathway is implicated in scar formation and fibrotic diseases at high activation levels